Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Alnylam Pharmaceuticals Inc shares valued at $11,621,956 were purchased by Greenstreet Yvonne on Nov 12 ’25. At $453.10 per share, Greenstreet Yvonne acquired 25,650 shares.
Also, Poulton Jeffrey V. sold 3,821 shares, netting a total of over 1,727,284 in proceeds. Following the sale of shares at $452.05 each, the insider now holds 54,052 shares.
Before that, Greenstreet Yvonne had sold 8,924 shares from its account. In a trade valued at $4,034,085, the Chief Executive Officer traded Alnylam Pharmaceuticals Inc shares for $452.05 each. Upon closing the transaction, the insider’s holdings decreased to 8,924 shares, worth approximately $29.61 million.
As published in a research note from Wolfe Research on August 04, 2025, Alnylam Pharmaceuticals Inc [ALNY] has been rated up from an Underperform to a Peer perform. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in early August. Earlier on July 21, 2025, Truist initiated its rating. Their recommendation was “a Buy” for ALNY stock.
Analyzing ALNY Stock Performance
On last trading session, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] rose 0.17% to $452.74. The stock’s lowest price that day was $447.13, but it reached a high of $459.2699 in the same session. During the last five days, there has been a surge of approximately 4.18%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 63.19%. Shares of the company reached a 52-week high of $495.55 on 10/20/25 and a 52-week low of $205.87 on 04/09/25.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 446.54, which, if violated, would cause prices to drop to 440.35. In the upper region, resistance lies at 459.10. The next price resistance is at 465.47. RSI (Relative Strength Index) is 49.35 on the 14-day chart, showing neutral technical sentiment.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp rise in short interest on 2025-10-31 jumping by 0.26 million shares to 3.77 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 3.51 million shares. A jump of 6.94% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.26 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.26.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 495 in the next 12 months, up nearly 9.53% from the previous closing price of $451.95. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 570 by 2025, with the lowest price target being 370. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2025. On March 31, 2025, Redburn Atlantic assigned a price target of “a Buy” to the stock and initiated coverage with a $353.
